Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)

NCT01668784 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

821

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma

Interventions

BIOLOGICAL: Nivolumab
DRUG: Everolimus

Sponsor

Bristol-Myers Squibb

Collaborators

[object Object]